The Cancer Letter Archives
The Cancer Letter was founded in 1973, two years after Congress passed the National Cancer Act of 1971. These archives represent the first 40 years of The Cancer Letter, which is published weekly.
CCL
Vol.
35
No.
7
July 27, 2012
- Six-Year Follow Up Of Phase III Sprycel Trial Demonstrates 71 Percent Overall Survival
- FDA Approves Afinitor-Aromasin Regimen For Advanced HER2-Negative Breast Cancer
- Phase III Study Evaluating Halaven Fails To Meet Primary Endpoints
- Upper Endoscopy Most Effective When Performed in 3-Year Intervals
- Women Who Concieve Using Fertility Drugs Have a Higher Risk Of Breast Cancer Than Non-Users
- Variation in Breast Density May Be Strong Risk Factor
- Study: Molecular Breast Imaging Can Be As Effective as MRI
- Mammography Had Limited Impact Among Swedish Women Age 40-69
- High Vitamin E Consumption Can Lower Liver Cancer Risks
- Gene Expression Test Accurately Classifies “Inconclusive” Samples
- CAP, ASCCP Recommendations Standardize Lesion Terminology
- NCI-Approved CTEP Trials For The Month of July
TCL
Vol.
38
No.
32
August 10, 2012
CCL
Vol.
35
No.
8
August 31, 2012
- Updated EMILIA Phase III Trial Results Confirm Increase in Overall Survival
- Study: HPV Testing Can Predict Precancers For Nearly Two Decades Following Exam
- Kyprolis Demonstrates Overall Response Following FDA Accelerated Approval
- Trastuzumab Increases Risks Of Congestive Heart Failure
- Breast Density Does Not Raise Breast Cancer Death Rates
- Amgen Halts Phase III Trial Of Ganitumab Plus Gemcitabine
- Spectral Mammography “Like Color vs. Black & White TV”
- Study Reveals Racial Disparities In Surgical Prostate Care
- 2,000 Breast Cancer Recurrence Biomarker Candidates Discovered
- NCI Approved CTEP Trials For the Month of August
- FDA Approves Afinitor Tablets For Advanced Breast Cancer
- Afinitor Suspension Approved For Rare Pediatric Brain Tumor
- FDA Approves Xtandi For Late-Stage Castration-Resistant Prostate Cancer